PAD4 deletion or inhibition of PAD4 by JBI-589 (12) reduced primary tumor growth and lung metastasis in mouse tumor models, significantly enhancing the effects of the immune checkpoint inhibitors, anti-CTLA-4 and anti-PD-1 antibodies [48] (Figure 5). Here, CTLA4 is linked to neoplasm.